Soria A, et al. Background: Combined BRAF/MEK inhibitors have demonstrated efficacy and tolerability in phase…
s.mengoni1 Dicembre 2023
Truong TG, et al. Background: Many patients with BRAF+ metastatic melanoma (MM) experience tumor progression…
s.mengoni1 Dicembre 2023
In GK, et al. Background: ENCO+BINI, a combination BRAF and MEK inhibitor therapy, prolonged OS…
s.mengoni1 Dicembre 2023
Hoeijmakers L, et al. Background: IMPemBra was the first trial testing intermittent, short-term, dabrafenib and…
s.mengoni1 Dicembre 2023
Gupta A, et al. Background: BRAF+MEK inhibitors extend life expectancy of BRAF V600 mutant advanced…
s.mengoni1 Dicembre 2023
Onofrio L, et al. Background: Among the most common causes of death in patients with…
s.mengoni30 Novembre 2023
Vitale M, et al. Background: Cancer patients (pts) with autoimmune diseases have been excluded from…
s.mengoni30 Novembre 2023
Cerro M, et al. Background: BRAF V600 mutations occur in 50% of cutaneous melanoma patients…
s.mengoni30 Novembre 2023
Buriolla S, et al. Background: The administration of SACT in the last month of life…
s.mengoni29 Novembre 2023
